Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combinatorial pharmacogenetics.

Russell A Wilke1, David M Reif, Jason H Moore

  • 1Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.

Nature Reviews. Drug Discovery
|November 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of in vitro profiling data of cosmetic ingredients within the Tox21 10K compound library for bioactivity and potential toxicity.

BMC pharmacology & toxicology·2026
Same author

Cross-sectoral and cross-agency team science: successful strategies from the National Center for Advancing Translational Sciences.

Frontiers in psychology·2026
Same author

Revisiting the modifiable areal unit problem in the era of exposome-wide association studies: Assessing the performance of the CDC/ATSDR social vulnerability index at privacy-protecting spatial scales.

Environmental research·2026
Same author

Impact of Chemical Quality on High-Throughput in Vitro Assays: A Tox21 Study.

Chemical research in toxicology·2026
Same author

Integrating qHTS and QSAR Models to Identify Safe GPCR-Targeted Compounds: A Focus on hERG-Dependent Cardiotoxicity.

Journal of chemical information and modeling·2026
Same author

Systematic evaluation of Tox21 compounds that target β-adrenergic receptors and their role in cardiotoxicity.

Toxicology and applied pharmacology·2025
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
See all related articles

Combinatorial pharmacogenetics studies genetic variations impacting drug metabolism and adverse drug reactions. Advanced analysis methods are crucial for understanding complex gene interactions and improving patient outcomes.

Area of Science:

  • Pharmacogenetics
  • Genomics
  • Drug Metabolism

Background:

  • Genetic variations in drug-metabolizing enzymes are common inheritable risk factors for adverse drug reactions.
  • Understanding these polymorphisms is key to predicting patient responses to medications.

Purpose of the Study:

  • To explore how genetic variations influence reactions to toxic agents within human metabolic networks.
  • To highlight the potential of combinatorial pharmacogenetics in clinical applications.

Main Methods:

  • Investigating polymorphic drug-metabolizing enzymes.
  • Characterizing genes involved in drug disposition (absorption, distribution, metabolism, elimination).
  • Employing novel analysis techniques like multifactor dimensionality reduction for high-dimensional data.

Related Experiment Videos

Main Results:

  • High concordance observed between drug-metabolizing enzyme polymorphisms and clinical phenotypes.
  • Identification of genetic factors influencing drug response.

Conclusions:

  • Combinatorial pharmacogenetics research holds significant promise for near-future patient benefit.
  • Advanced analytical approaches are necessary to manage the complexity of gene-drug interaction data.